US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neumora Therapeutics, Inc.

0.7670

+0.00440.58%

Pre-market: 0.78490.0179+2.33%08:08 EDT

Volume:651.41K

Turnover:494.12K

Market Cap:124.06M

PE:-0.50

High:0.7899

Open:0.7817

Low:0.7411

Close:0.7626

Loading ...

Overview Company News Filings

Neumora Therapeutics Announces Leadership Changes and Strategy

Neumora Therapeutics Names Paul Berns as CEO, Michael Milligan as CFO

MT Newswires Live

Neumora Therapeutics Announces Leadership Transition

THOMSON REUTERS

Neumora Therapeutics Inc - Paul L. Berns to Serve as CEO and Chairman of Neumora

THOMSON REUTERS

Neumora Therapeutics Inc - BILL Aurora to Serve as COO and Cdo, Michael Milligan as CFO

THOMSON REUTERS

Neumora Therapeutics Announces Leadership Transition

Levi & Korsinsky LLP Reminds Shareholders of a Lead Plaintiff Deadline of April 07, 2025 in Neumora Therapeutics, Inc. Lawsuit – NMRA

3 US Penny Stocks With Market Caps Over $30M To Watch

Simply Wall St.

Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More

Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA) and Idexx Laboratories (IDXX)

Neumora Therapeutics price target lowered to $7 from $22 at BofA

Neumora shares look oversold after 80% drop, says Mizuho

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

MT Newswires Live

Neumora Therapeutics Up Over 16%, on Pace for Largest Percent Increase Since December 2023 -- Data Talk

Neumora Has 2 More Chances With Navacaprant After Readout Miss, Mizuho Says

MT Newswires Live

Neumora Stock Hits Record Low on Depression Drug Study Failure

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Natera (NTRA) and Neumora Therapeutics, Inc. (NMRA)

Neumora Therapeutics Selloff Seen as Overdone -- Market Talk

U.S. Small Caps Close Mixed As Rigetti Computing Lead, Neumora Therapeutics Lags

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NMRA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","market":"US","secType":"STK","nameCN":"Neumora Therapeutics, Inc.","latestPrice":0.767,"timestamp":1745956800000,"preClose":0.7626,"halted":0,"volume":651407,"hourTrading":{"tag":"盘前","latestPrice":0.7849,"preClose":0.767,"latestTime":"08:08 EDT","volume":3,"amount":2.3697,"timestamp":1746014886423},"delay":0,"floatShares":53514397,"shares":161747922,"eps":-1.529624,"marketStatus":"Pre-Mkt","change":0.0044,"latestTime":"04-30 09:26:21 EDT","open":0.7817,"high":0.789899,"low":0.7411,"amount":494124.3238651,"amplitude":0.06399,"askPrice":0.9658,"askSize":500,"bidPrice":0.525,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.529624,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746019800000},"marketStatusCode":1,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":0.767,"preHourTrading":{"tag":"盘前","latestPrice":0.7849,"preClose":0.767,"latestTime":"08:08 EDT","volume":3,"amount":2.3697,"timestamp":1746014886423},"postHourTrading":{"tag":"盘后","latestPrice":0.7727,"preClose":0.767,"latestTime":"19:56 EDT","volume":28542,"amount":21858.7826,"timestamp":1745970996380},"volumeRatio":0.6327791217099019,"impliedVol":0.8389,"impliedVolPercentile":0.3454},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","floatShares":53514397,"roa":"-40.50%","roe":"-64.48%","lyrEps":-1.529624,"volumeRatio":0.6327791217099019,"shares":161747922,"dividePrice":0,"high":0.789899,"amplitude":0.06399,"preClose":0.7626,"low":0.7411,"week52Low":0.6211,"pbRate":"0.43","week52High":17.1874,"institutionHeld":0,"latestPrice":0.767,"committee":-0.428571,"eps":-1.529624,"divideRate":0,"volume":651407,"delay":0,"ttmEps":-1.529624,"open":0.7817,"prevYearClose":10.6,"fiveDayClose":0.705,"twentyDayClose":1,"sixtyDayClose":1.93,"earningDate":1746979200000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NMRA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2511505975","title":"Neumora Therapeutics Announces Leadership Changes and Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2511505975","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511505975?lang=en_us&edition=fundamental","pubTime":"2025-02-14 06:17","pubTimestamp":1739485076,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc. ( ($NMRA) ) has shared an update. On February 13, 2025, Neumora Therapeutics announced leadership changes effective Febr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neumora-therapeutics-announces-leadership-changes-and-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neumora-therapeutics-announces-leadership-changes-and-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA","BK4023","BK4139","BK4588","STRK","BK4007","BK4516","LENZ","BK4595","BK4585","BK4596","BK4600"],"gpt_icon":0},{"id":"2511526900","title":"Neumora Therapeutics Names Paul Berns as CEO, Michael Milligan as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2511526900","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511526900?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:57","pubTimestamp":1739455057,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NMRA) said Thursday that Paul Berns, its co-founder and executive chair of the board, has been named to succeed Henry Gosebruch as chief executive officer, effective Friday.The c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","NMRA","BK4007"],"gpt_icon":0},{"id":"2511546707","title":"Neumora Therapeutics Announces Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2511546707","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511546707?lang=en_us&edition=fundamental","pubTime":"2025-02-13 20:00","pubTimestamp":1739448003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUA1ZS0DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2511467945","title":"Neumora Therapeutics Inc - Paul L. Berns to Serve as CEO and Chairman of Neumora","url":"https://stock-news.laohu8.com/highlight/detail?id=2511467945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511467945?lang=en_us&edition=fundamental","pubTime":"2025-02-13 20:00","pubTimestamp":1739448003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUA1ZS0DV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2511460535","title":"Neumora Therapeutics Inc - BILL Aurora to Serve as COO and Cdo, Michael Milligan as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2511460535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511460535?lang=en_us&edition=fundamental","pubTime":"2025-02-13 20:00","pubTimestamp":1739448003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUA1ZS0DV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2511954955","title":"Neumora Therapeutics Announces Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2511954955","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511954955?lang=en_us&edition=fundamental","pubTime":"2025-02-13 20:00","pubTimestamp":1739448000,"startTime":"0","endTime":"0","summary":"Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board. Bill Aurora, Pharm.D. to serve as chief operating and development officer; Michael Milligan to serve as chief financial officer. “Neumora is poised to reach its potential, working to maximize shareholder value, and most importantly, to make a difference for the millions of people living with brain diseases,” said Paul L. Berns. “We have seven novel neuroscience programs in the pipeline and four clinical data readouts on the horizon, including data from the ongoing Phase 3 program with navacaprant in depression. This provides significant opportunities to improve the treatment of brain diseases and address unmet needs by bringing novel medicines to people who need them most.”“I am honored to serve as president of Neumora,” said Dr. Joshua Pinto. “Neumora is in a strong position, advancing studies in some of the most prevalent brain diseases with multiple near-term ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neumora-therapeutics-announces-leadership-transition-120000381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LENZ","BK4007","NMRA"],"gpt_icon":0},{"id":"2509776188","title":"Levi & Korsinsky LLP Reminds Shareholders of a Lead Plaintiff Deadline of April 07, 2025 in Neumora Therapeutics, Inc. Lawsuit – NMRA","url":"https://stock-news.laohu8.com/highlight/detail?id=2509776188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509776188?lang=en_us&edition=fundamental","pubTime":"2025-02-08 04:40","pubTimestamp":1738960803,"startTime":"0","endTime":"0","summary":"THE LAWSUIT: This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/levi-korsinsky-llp-reminds-shareholders-of-a-lead-plaintiff-deadline-of-april-07-2025-in-neumora-therapeutics-inc-lawsuit-nmra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/levi-korsinsky-llp-reminds-shareholders-of-a-lead-plaintiff-deadline-of-april-07-2025-in-neumora-therapeutics-inc-lawsuit-nmra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2502886610","title":"3 US Penny Stocks With Market Caps Over $30M To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2502886610","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502886610?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:13","pubTimestamp":1736514807,"startTime":"0","endTime":"0","summary":"As the U.S. stock market experiences slight declines with investors eagerly awaiting the December jobs report, attention turns to the potential impact on interest rates and economic resilience. In this context, penny stocks—often smaller or newer companies—remain a relevant investment area due to their affordability and growth potential. Despite being considered a throwback term, these stocks can offer significant opportunities when backed by strong financials, presenting intriguing prospects for investors seeking hidden value in today's market landscape.Overview: Giftify, Inc. owns and operates a restaurant deal space in the United States with a market cap of $31.41 million.PodcastOne, Inc., with a market cap of US$55.72 million, is trading well below estimated f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-us-penny-stocks-market-131327070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","PODC","BK4213","BK4563","SB","BK4209","BK4021","PVL","GIFT","BABB","BK4077","NMRA"],"gpt_icon":0},{"id":"2502022643","title":"Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2502022643","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502022643?lang=en_us&edition=fundamental","pubTime":"2025-01-10 02:48","pubTimestamp":1736448480,"startTime":"0","endTime":"0","summary":"It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on the announcement of a study failure, while Hoth Therapeutics HOTH gained on study data.Neumora Therapeutics announced the failure of its lead pipeline candidate, navacaprant, in a late-stage study for major depressive disorder . Shares of the company plummeted on the same.The phase III KOASTAL-1 study evaluated the efficacy and safety of navacaprant against placebo in adults with moderate-to-severe MDD over a six-week treatment period. The study failed to achieve its primary endpoint. Treatment with the drug failed to demonstrate a significant improvement over placebo in alleviating depression symptoms, as measured by the Montgomery-Asberg Depression Rating Scale.The study also failed to show statistically significant improvement in the reduction of anhedonia , as assessed by the Snaith-Hamilton Pleasure Scale.Per the terms, Teva has agreed not to market its gener","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-nmra-plunges-184800572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VIR","HOTH","BK4217","BK4568","PSA","CPRX","BK4533","TEVA","BK4584","BK4559","BK4535","BK4007","BK4588","BK4566","BK4596","BK4585","BK4557","BK4139","NMRA","BK4084"],"gpt_icon":1},{"id":"2501423781","title":"Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA) and Idexx Laboratories (IDXX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2501423781","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501423781?lang=en_us&edition=fundamental","pubTime":"2025-01-06 08:10","pubTimestamp":1736122226,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neumora Therapeutics, Inc. (NMRA – Research Report) and Idexx Lab...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-neumora-therapeutics-inc-nmra-and-idexx-laboratories-idxx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-neumora-therapeutics-inc-nmra-and-idexx-laboratories-idxx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LU0690374615.EUR","NMRA","GB00B4QBRK32.GBP","BK4504","BK4567","HCSG","BK4585","LU0170899867.USD","LU2404859741.USD","BK4007","BK4588","LU1941712264.USD","BK4082","GB00B4LPDJ14.GBP","LU1941712348.USD","LU1291159041.SGD","LU2404859667.USD","LU0690374961.EUR","LU1989771016.USD","IDXX"],"gpt_icon":0},{"id":"2501423784","title":"Neumora Therapeutics price target lowered to $7 from $22 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2501423784","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501423784?lang=en_us&edition=fundamental","pubTime":"2025-01-06 08:00","pubTimestamp":1736121618,"startTime":"0","endTime":"0","summary":"BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares. The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-price-target-lowered-to-7-from-22-at-bofa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-price-target-lowered-to-7-from-22-at-bofa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2500433585","title":"Neumora shares look oversold after 80% drop, says Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2500433585","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500433585?lang=en_us&edition=fundamental","pubTime":"2025-01-04 21:00","pubTimestamp":1735995645,"startTime":"0","endTime":"0","summary":"Mizuho keeps an Outperform rating on Neumora Therapeutics  after the company announced negative first Phase 3 KOASTAL-1/K-1 study data for navacaprant in major depressive disorder. With navacaprant missing on both primary and secondary endpoints, a disappointing outcome, the stock’s 80% drop is not surprising, the analyst tells investors in a research note. The firm reminds investors that Neumora has two more shots on goal with navacaprant, with the Phase 3 KOASTAL-2/K-2 and KOASTAL-3/ K-3 studies ongoing, and data readouts from both expected in the first half of 2025. With Neumora now trading at negative enterprise value, but having a cash runway to mid-2026 and other pipeline programs, the shares look oversold, contends Mizuho.Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. H.C. Wainwright still sees opportunity for Neumora despite ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neumora-shares-look-oversold-80-130045875.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neumora-shares-look-oversold-80-130045875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4207","BK4007","MFG","NMRA"],"gpt_icon":0},{"id":"2500129566","title":"Sector Update: Health Care Stocks Rise in Late Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2500129566","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500129566?lang=en_us&edition=fundamental","pubTime":"2025-01-04 04:58","pubTimestamp":1735937883,"startTime":"0","endTime":"0","summary":"Health care stocks advanced late Friday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund  both adding 0.9%.The iShares Biotechnology ETF  also climbed 0.9%.In corporate news, IceCure Medical  shares rose 4.9% after the company received an intention to grant notice from the European Patent Office for its cryoablation technology.Bionano Genomics  shares jumped 20%. The company announced a registered direct offering to certain institutional investors for almost 39.7 million shares and related warrants at $0.252 apiece to raise $10 million.Cyclacel Pharmaceuticals  shares surged 26% after investor David Lazar agreed to buy $3.1 million in the company's preferred stock and was named interim chief executive.Neumora Therapeutics'  readout of its first phase 3 trial of navacaprant in major depressive disorder was a \"significant miss,\" though the company has two more chances, Mizuho Securities said in a report. Neumora shares rose 13%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BNGO","NMRA","CYCC","BK4082","ICCM","XLV","BK4585","IBB","BK4581","BK4575","BK4139","BK4588","BK4007","BK4121"],"gpt_icon":1},{"id":"2500143648","title":"Neumora Therapeutics Up Over 16%, on Pace for Largest Percent Increase Since December 2023 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2500143648","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500143648?lang=en_us&edition=fundamental","pubTime":"2025-01-04 00:05","pubTimestamp":1735920300,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc.  is currently at $2.30, up $0.33 or 16.5%. --On pace for largest percent increase since Dec. 22, 2023, when it rose 25.09%. --Down 88.39% from its all-time closing high of $19.76 on Feb. 16, 2024. --Down 85.60% from 52 weeks ago , when it closed at $15.94. --Up 16.5% from its 52-week closing low of $1.97 on Jan. 2, 2025. --Up 25.89% at today's intraday high; largest intraday percent increase since Dec. 22, 2023, when it rose as much as 37.96%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LENZ","NMRA"],"gpt_icon":0},{"id":"2500148362","title":"Neumora Has 2 More Chances With Navacaprant After Readout Miss, Mizuho Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2500148362","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500148362?lang=en_us&edition=fundamental","pubTime":"2025-01-03 23:47","pubTimestamp":1735919244,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics'  readout of its first phase 3 trial of navacaprant in major depressive disorder was a \"significant miss,\" but the company still has two more chances to go, Mizuho Securities said in a note Friday.Two phase 3 trials are still ongoing, with topline data readouts from both studies slated for H1, Mizuho analyst Graig Suvannavejh said, adding the company can make adjustments to these two studies given the negative results from the first trial although timelines might be affected.The company is expected to provide a navacaprant program update in the next few weeks and Mizuho said it will wait for that update before revisiting its estimates and views on the company.\"With [Neumora] now trading at negative enterprise value, but having a cash runway to mid-2026 and other pipeline programs, the shares look oversold,\" according to the note.Mizuho has an outperform rating on Neumora and $20 price target.Neumora shares were rising more than 18% in recent trading.Price: 2.33, Ch","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMRA","MFG","BK4207","BK4007"],"gpt_icon":0},{"id":"2500145917","title":"Neumora Stock Hits Record Low on Depression Drug Study Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2500145917","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500145917?lang=en_us&edition=fundamental","pubTime":"2025-01-03 22:14","pubTimestamp":1735913640,"startTime":"0","endTime":"0","summary":"The phase III KOASTAL-1 study evaluated the efficacy and safety of navacaprant against placebo in adults with moderate-to-severe MDD over a six-week treatment period. The study failed to achieve its primary endpoint – treatment with the drug failed to demonstrate a significant improvement over placebo in alleviating depression symptoms, as measured by the Montgomery-Asberg Depression Rating Scale .The study also failed to show statistically significant improvement in the reduction of anhedonia , as assessed by the Snaith-Hamilton Pleasure Scale .The KOASTAL-1 study is one of the three late-stage studies in the KOASTAL program evaluating navacaprant in the MDD indication. Despite the study's failure, Neumora intends to continue the other two studies. In the meantime, management continues to further analyze the study results, as management claimed that the drug showed an efficacy signal in female patients.Following the news, shares of Neumora hit an all-time low of $1.83. The latest anno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neumora-stock-hits-record-low-141400263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRO","ABVC","CTMX","CSTL","BK4196","BK4139","BK4007","NMRA"],"gpt_icon":0},{"id":"2500611313","title":"Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Natera (NTRA) and Neumora Therapeutics, Inc. (NMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2500611313","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500611313?lang=en_us&edition=fundamental","pubTime":"2025-01-03 21:10","pubTimestamp":1735909813,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZ – Research Report), Nater...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-jazz-pharmaceuticals-jazz-natera-ntra-and-neumora-therapeutics-inc-nmra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-jazz-pharmaceuticals-jazz-natera-ntra-and-neumora-therapeutics-inc-nmra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU1988902786.USD","LU2065731478.USD","LU0109394709.USD","BK4137","LU0053671581.USD","LU2065169927.USD","LU2264538146.SGD","BK4532","BK4007","BK4533","JAZZ","LU2065170008.USD","LU0012050646.USD","NMRA","LU0889565916.HKD","HCSG","LU2065171402.SGD","LU0106261612.USD","LU2065171311.SGD","LU0320765992.SGD","NTRA","LU1064131342.USD"],"gpt_icon":0},{"id":"2500119004","title":"Neumora Therapeutics Selloff Seen as Overdone -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2500119004","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500119004?lang=en_us&edition=fundamental","pubTime":"2025-01-03 20:50","pubTimestamp":1735908600,"startTime":"0","endTime":"0","summary":"0750 ET - Neumora Therapeutics shares look oversold after Thursday's 81% plunge on the heels of a failed Phase 3 study of the biotech's experimental depression drug, Mizuho says. In a research note, analyst Graig Suvannavejh says Neumora now trades at a negative enterprise value despite having a cash runway to mid-2026 and other pipeline programs. Mizuho also notes that Neumora still has two more navacaprant Phase 3 studies ongoing, and that many antidepressants have had at least one Phase 3 failure before winning approval. Neumora up 4.5% premarket to $2.06. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NMRA","BK4007","BK4139"],"gpt_icon":0},{"id":"2500902567","title":"U.S. Small Caps Close Mixed As Rigetti Computing Lead, Neumora Therapeutics Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2500902567","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500902567?lang=en_us&edition=fundamental","pubTime":"2025-01-03 05:20","pubTimestamp":1735852800,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies were mixed Thursday, as the Russell 2000 Index gained 0.1%, while the S&P Small Cap 600 Index was down 0.2%.Among companies with a market value of $1 billion to $6.7 billion, Rigetti Computing Inc. was the best performer during the session, surging 31%, followed by Denison Mines Corp., which surged 16%. Topgolf Callaway Brands Corp. shares jumped 15%, D-Wave Quantum Inc. surged 14%, and shares of Uranium Energy Corp. surged 14%.Neumora Therapeutics Inc. was the biggest laggard, dropping 81%, followed by shares of Nexa Resources S.A., which dropped 18%. Shares of RealReal Inc. dropped 10%, Blend Labs Inc. shares plunged 8.8%, and U.S. Lime & Minerals Inc. tumbled 8.0%.Major U.S. stock indexes closed down Thursday as the Nasdaq Composite Index declined 0.2%. Meanwhile, the S&P 500 Index fell 0.2%, and the Dow Jones Industrial Average dropped 0.4%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4602","RGTI","BK4007","LENZ","BK4141","BK4139","NMRA"],"gpt_icon":1},{"id":"2500904326","title":"Sector Update: Health Care Stocks Softer Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2500904326","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500904326?lang=en_us&edition=fundamental","pubTime":"2025-01-03 04:57","pubTimestamp":1735851467,"startTime":"0","endTime":"0","summary":"Health care stocks were declining late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund  both fractionally lower.The iShares Biotechnology ETF  rose 0.4%.In corporate news, Pfizer  is collaborating with Atavistik Bio to accelerate the discovery of new precision allosteric therapeutics, Atavistik said. Pfizer shares added 0.5%.BioNexus Gene Lab  shares soared 45%. The company said that it was granted temporary exception until May 1 to regain compliance with Nasdaq's minimum bid price rule.NRX Pharmaceuticals  shares surged 35%. The company's Hope Therapeutics unit plans to acquire the Kadima Neuropsychiatry Institute.Neumora Therapeutics  shares plunged past 81% after a phase 3 trial of navacaprant to treat major depressive disorder failed to meet the primary endpoint.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1894683348.USD","LU0306806265.USD","LU0170899867.USD","LU0456855351.SGD","LU0225771236.USD","LU0321505868.SGD","LU0289739699.SGD","LU0321505439.SGD","LU1883839398.USD","BK4568","BK4592","LU1057294990.SGD","IE000M9KFDE8.USD","IE00B19Z3581.USD","NMRA","LU0234572021.USD","SG9999001176.SGD","LU1023059063.AUD","PFE.AU","SG9999003800.SGD","IE00BLSP4239.USD","IBB","IE0002270589.USD","LU0985481810.HKD","BK4588","LU0058720904.USD","IE00BLSP4452.SGD","BK4007","NRXP","BK4599","PFE","LU0122379950.USD","LU0868494617.USD","SG9999002224.SGD","LU0225284248.USD","IE00B19Z3B42.SGD","BK4104","SG9999002232.USD","BK4581","SG9999013999.USD","BK4550","BGLC","SG9999001176.USD","BK4534","SGXZ57979304.SGD","XLV","LU1066053197.SGD","IE00BBT3K403.USD","BK4585","SG9999011175.SGD"],"gpt_icon":1}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":115,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NMRA\",params:#limit:5,,,undefined,":[{"date":"2025-05-12","symbol":"NMRA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"defaultRemindTime":1747080000000,"name":null,"time":"Post Market","dateTimestamp":1747022400000,"actualEps":null},{"market":"US","date":"2024-11-12","symbol":"NMRA","fiscalQuarterEnding":"2024/09","expectedEps":-0.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.5556,"sell":0.1111,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.5556,"analysts":9,"updateTime":1743566400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NMRA","date":"2025-04-29","current":-0.50597,"percent":0.960317,"low":-19.620035,"twenty":-12.279982,"median":-6.898905,"eighty":-1.320222,"high":-0.41859,"avg":-7.884911,"sd":5.021329,"marketCap":123348965},"quantilePoints":[{"date":"2023-09-15","current":-19.620035,"twenty":-19.620035,"median":-19.620035,"eighty":-19.620035,"marketCap":2583134632},{"date":"2023-09-22","current":-12.753675,"twenty":-18.754446,"median":-15.453663,"eighty":-12.753675,"marketCap":1679123396},{"date":"2023-09-28","current":-13.691957,"twenty":-17.415667,"median":-13.628246,"eighty":-12.772209,"marketCap":1802655635},{"date":"2023-10-05","current":-13.813351,"twenty":-16.65135,"median":-13.723658,"eighty":-12.773914,"marketCap":1818638110},{"date":"2023-10-13","current":-11.180579,"twenty":-14.994038,"median":-13.691957,"eighty":-12.763183,"marketCap":1472012710},{"date":"2023-10-20","current":-11.493728,"twenty":-13.94093,"median":-13.080265,"eighty":-11.639864,"marketCap":1513241282},{"date":"2023-10-27","current":-14.254079,"twenty":-14.080107,"median":-13.080265,"eighty":-11.690896,"marketCap":1876663508},{"date":"2023-11-03","current":-10.734234,"twenty":-13.848145,"median":-12.776843,"eighty":-11.493728,"marketCap":1667466680},{"date":"2023-11-10","current":-10.420012,"twenty":-13.826354,"median":-12.7442,"eighty":-11.403032,"marketCap":1618655149},{"date":"2023-11-17","current":-11.79624,"twenty":-13.813351,"median":-12.154821,"eighty":-11.403032,"marketCap":1832439792},{"date":"2023-11-24","current":-11.717599,"twenty":-13.766958,"median":-11.806071,"eighty":-11.438475,"marketCap":1820223526},{"date":"2023-12-01","current":-12.041995,"twenty":-13.704638,"median":-11.815901,"eighty":-11.48267,"marketCap":1870615621},{"date":"2023-12-08","current":-12.26809,"twenty":-13.59002,"median":-11.825731,"eighty":-11.493283,"marketCap":1905737383},{"date":"2023-12-15","current":-14.381583,"twenty":-13.717318,"median":-11.894542,"eighty":-11.493728,"marketCap":2234049513},{"date":"2023-12-22","current":-13.75245,"twenty":-13.821153,"median":-12.041995,"eighty":-11.521564,"marketCap":2136319390},{"date":"2023-12-29","current":-16.848963,"twenty":-14.008036,"median":-12.137729,"eighty":-11.563317,"marketCap":2617334836},{"date":"2024-01-05","current":-16.111698,"twenty":-14.24211,"median":-12.26809,"eighty":-11.573312,"marketCap":2502807349},{"date":"2024-01-12","current":-14.991056,"twenty":-14.660761,"median":-12.728927,"eighty":-11.585874,"marketCap":2328725569},{"date":"2024-01-19","current":-14.411074,"twenty":-14.428768,"median":-12.751722,"eighty":-11.613398,"marketCap":2238630612},{"date":"2024-01-26","current":-14.843603,"twenty":-15.020547,"median":-12.776843,"eighty":-11.648787,"marketCap":2305820071},{"date":"2024-02-02","current":-14.991056,"twenty":-15.264335,"median":-13.370218,"eighty":-11.652719,"marketCap":2328725569},{"date":"2024-02-09","current":-17.1537,"twenty":-15.346909,"median":-13.691957,"eighty":-11.671529,"marketCap":2664672864},{"date":"2024-02-16","current":-18.490607,"twenty":-15.539581,"median":-13.783396,"eighty":-11.691031,"marketCap":2872349373},{"date":"2024-02-23","current":-18.500437,"twenty":-15.932789,"median":-13.819852,"eighty":-11.69454,"marketCap":2873876407},{"date":"2024-03-01","current":-17.330643,"twenty":-16.668088,"median":-13.939224,"eighty":-11.709735,"marketCap":2692159461},{"date":"2024-03-08","current":-12.297819,"twenty":-16.990518,"median":-13.97363,"eighty":-11.717599,"marketCap":2901363004},{"date":"2024-03-15","current":-10.189453,"twenty":-16.81554,"median":-13.826354,"eighty":-11.69454,"marketCap":2403946708},{"date":"2024-03-22","current":-9.414974,"twenty":-16.668088,"median":-13.783396,"eighty":-11.650753,"marketCap":2221227691},{"date":"2024-03-28","current":-8.492333,"twenty":-16.613039,"median":-13.722203,"eighty":-11.579976,"marketCap":2003553733},{"date":"2024-04-05","current":-9.246609,"twenty":-16.364935,"median":-13.534996,"eighty":-11.491504,"marketCap":2181506166},{"date":"2024-04-12","current":-9.435178,"twenty":-16.111698,"median":-12.865966,"eighty":-11.216259,"marketCap":2225994275},{"date":"2024-04-19","current":-7.105005,"twenty":-15.954415,"median":-12.753675,"eighty":-10.606446,"marketCap":1676248365},{"date":"2024-04-26","current":-6.123304,"twenty":-15.846283,"median":-12.728927,"eighty":-10.162515,"marketCap":1444640411},{"date":"2024-05-03","current":-6.231441,"twenty":-15.669339,"median":-12.297819,"eighty":-9.792112,"marketCap":1470152824},{"date":"2024-05-10","current":-6.135514,"twenty":-15.610358,"median":-12.155389,"eighty":-9.435178,"marketCap":1558549450},{"date":"2024-05-17","current":-6.047595,"twenty":-15.433415,"median":-12.120637,"eighty":-9.273547,"marketCap":1536216091},{"date":"2024-05-24","current":-5.846636,"twenty":-15.423584,"median":-11.91675,"eighty":-8.957021,"marketCap":1485168412},{"date":"2024-05-31","current":-6.085275,"twenty":-15.399992,"median":-11.884712,"eighty":-8.469435,"marketCap":1545787530},{"date":"2024-06-07","current":-6.235993,"twenty":-15.362637,"median":-11.806071,"eighty":-7.09423,"marketCap":1584073290},{"date":"2024-06-14","current":-6.248553,"twenty":-15.342977,"median":-11.75692,"eighty":-6.904314,"marketCap":1587263770},{"date":"2024-06-21","current":-5.557759,"twenty":-15.335113,"median":-11.717599,"eighty":-6.419582,"marketCap":1411787373},{"date":"2024-06-28","current":-5.777557,"twenty":-15.335113,"median":-11.707769,"eighty":-6.279953,"marketCap":1467620772},{"date":"2024-07-05","current":-6.129234,"twenty":-15.228947,"median":-11.690896,"eighty":-6.264891,"marketCap":1556954210},{"date":"2024-07-12","current":-7.253346,"twenty":-15.12278,"median":-11.653703,"eighty":-6.277441,"marketCap":1842502165},{"date":"2024-07-15","current":-6.939348,"twenty":-15.110984,"median":-11.648787,"eighty":-6.278697,"marketCap":1762740166},{"date":"2024-08-02","current":-7.931581,"twenty":-15.099188,"median":-11.648787,"eighty":-6.279953,"marketCap":2014788082},{"date":"2024-08-09","current":-6.56038,"twenty":-15.040207,"median":-11.579976,"eighty":-6.279953,"marketCap":1798711865},{"date":"2024-08-16","current":-6.881395,"twenty":-14.991056,"median":-11.493728,"eighty":-6.279953,"marketCap":1886727125},{"date":"2024-08-23","current":-6.712133,"twenty":-14.991056,"median":-11.447336,"eighty":-6.393648,"marketCap":1840319079},{"date":"2024-08-30","current":-6.54287,"twenty":-14.922244,"median":-11.299816,"eighty":-6.436952,"marketCap":1793911032},{"date":"2024-09-06","current":-6.297731,"twenty":-14.859331,"median":-10.957407,"eighty":-6.374465,"marketCap":1726699379},{"date":"2024-09-13","current":-6.904742,"twenty":-14.68632,"median":-10.606446,"eighty":-6.374465,"marketCap":1893128235},{"date":"2024-09-20","current":-7.430039,"twenty":-14.481851,"median":-10.304733,"eighty":-6.410301,"marketCap":2037153206},{"date":"2024-09-27","current":-7.634321,"twenty":-14.416972,"median":-9.973946,"eighty":-6.432454,"marketCap":2093162917},{"date":"2024-10-04","current":-7.905725,"twenty":-14.387481,"median":-9.835887,"eighty":-6.454177,"marketCap":2167575819},{"date":"2024-10-11","current":-8.988421,"twenty":-14.365855,"median":-9.536197,"eighty":-6.471402,"marketCap":2464427288},{"date":"2024-10-18","current":-9.898936,"twenty":-14.275648,"median":-9.492422,"eighty":-6.494727,"marketCap":2714070572},{"date":"2024-10-25","current":-7.587628,"twenty":-14.23812,"median":-9.435178,"eighty":-6.5109,"marketCap":2080360698},{"date":"2024-10-31","current":-7.126534,"twenty":-14.186945,"median":-9.414974,"eighty":-6.517189,"marketCap":1953938778},{"date":"2024-11-08","current":-7.599301,"twenty":-14.11026,"median":-9.329429,"eighty":-6.519524,"marketCap":2083561252},{"date":"2024-11-15","current":-6.430581,"twenty":-14.036864,"median":-9.246609,"eighty":-6.508113,"marketCap":1888648838},{"date":"2024-11-22","current":-5.330396,"twenty":-14.008036,"median":-9.078889,"eighty":-6.434404,"marketCap":1565526710},{"date":"2024-11-29","current":-5.467919,"twenty":-13.980511,"median":-8.972721,"eighty":-6.336098,"marketCap":1605916976},{"date":"2024-12-06","current":-5.313893,"twenty":-13.902792,"median":-8.614876,"eighty":-6.276185,"marketCap":1560679878},{"date":"2024-12-13","current":-5.819979,"twenty":-13.839429,"median":-8.495238,"eighty":-6.248553,"marketCap":1709316057},{"date":"2024-12-20","current":-5.775971,"twenty":-13.821153,"median":-8.377845,"eighty":-6.222869,"marketCap":1696391172},{"date":"2024-12-27","current":-6.238049,"twenty":-13.812967,"median":-8.200475,"eighty":-6.175381,"marketCap":1832102465},{"date":"2025-01-03","current":-1.083682,"twenty":-13.811432,"median":-8.147945,"eighty":-6.157876,"marketCap":318275296},{"date":"2025-01-10","current":-1.303719,"twenty":-13.766574,"median":-7.931581,"eighty":-6.140538,"marketCap":382899721},{"date":"2025-01-17","current":-1.193701,"twenty":-13.753032,"median":-7.891133,"eighty":-6.119668,"marketCap":350587508},{"date":"2025-01-24","current":-1.1882,"twenty":-13.716154,"median":-7.812392,"eighty":-6.085275,"marketCap":348971898},{"date":"2025-01-31","current":-1.056178,"twenty":-13.615504,"median":-7.634321,"eighty":-6.067691,"marketCap":310197242},{"date":"2025-02-07","current":-1.07268,"twenty":-13.546812,"median":-7.564281,"eighty":-5.978405,"marketCap":315044074},{"date":"2025-02-14","current":-0.929656,"twenty":-13.337262,"median":-7.53602,"eighty":-5.966304,"marketCap":273038198},{"date":"2025-02-21","current":-0.940658,"twenty":-13.1053,"median":-7.470895,"eighty":-5.920328,"marketCap":276269419},{"date":"2025-02-28","current":-0.852643,"twenty":-12.883791,"median":-7.424202,"eighty":-5.847483,"marketCap":250419649},{"date":"2025-03-07","current":-1.009931,"twenty":-12.773914,"median":-7.253346,"eighty":-5.800175,"marketCap":246207962},{"date":"2025-03-14","current":-0.930199,"twenty":-12.763183,"median":-7.144044,"eighty":-5.763741,"marketCap":226770492},{"date":"2025-03-21","current":-0.770737,"twenty":-12.752113,"median":-7.105005,"eighty":-5.687956,"marketCap":187895550},{"date":"2025-03-28","current":-0.730871,"twenty":-12.743752,"median":-7.036301,"eighty":-5.574632,"marketCap":178176815},{"date":"2025-04-04","current":-0.564099,"twenty":-12.730087,"median":-6.998128,"eighty":-5.417311,"marketCap":137520105},{"date":"2025-04-11","current":-0.476129,"twenty":-12.580434,"median":-6.945391,"eighty":-5.374404,"marketCap":116074096},{"date":"2025-04-17","current":-0.41859,"twenty":-12.352677,"median":-6.926527,"eighty":-5.321594,"marketCap":102046721},{"date":"2025-04-25","current":-0.497989,"twenty":-12.291873,"median":-6.904742,"eighty":-1.375231,"marketCap":121403202},{"date":"2025-04-29","current":-0.50597,"twenty":-12.279982,"median":-6.898905,"eighty":-1.320222,"marketCap":123348965}],"updateTime":1746019581319}}}